** Shares of drug distributor Cencora COR.N rise 1.7% to $255.77
** Co raises fiscal 2025 profit forecast, driven by robust demand for expensive specialty medicines
** Expects 2025 adj. profit to range between $15.25 and $15.55 per share, up from previous view of $15.15 to $15.45
** Reports adj. Q1 profit of 3.73 per share, beating estimates of $3.50 per share - data compiled by LSEG
** Q1 sales in its U.S. healthcare solutions segment rose 13.6% to $74.0 billion
** "COR is off to a strong year stock-wise, but we see this quarter/guidance as another reason to see further upside on both estimates and multiple expansion," brokerage Leerink Partners says
** Stock rose 9.4% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.